# Celgene: portfolio, investments and team

> Celgene is a growth equity based in United States. 33 investments on record, latest Jul 2019. Portfolio, stages, co-investors and team.

Source: https://millionrounds.com/fund/celgene (Millionrounds; every figure on the page links to its filing or article)

United States · [Investor](https://millionrounds.com/investors)

# Celgene

Last cheque observed Jul 2019. Silence since then is not evidence of inactivity: our sources miss unannounced rounds.

Quiet Growth equity

Series B Series D Series C

Cheques on record

**0%** of best year **0** **cheques in 12 months**, 33 on record

Since the last cheque **2666** days **00** hrs **00** min **00** sec

Median round **$61M** Rounds led **0 of 33** Sole investor **8 rounds** Exits **3 from the portfolio** Mostly in **United States, 97%**

Pitch Celgene

## Celgene highlights

- 01 33 rounds on record
- 02 Mostly Series B and Series D: 65% of its rounds
- 03 Sole investor in 8 rounds, median $30M
- 04 3 exits from the portfolio

## What they do

- **Type:** Growth equity (from a list, unverified)
- **Cheque size:** Not stated
- **Based in:** San Diego, United States
- **Cold pitches:** Not stated

## The record

Every round we can evidence, newest first **33 appearances**

- **2019** 3 rounds
- **Jul** **[GNS Healthcare](https://millionrounds.com/company/gns-healthcare)** Series D · US · FinSMEs **$23M** With 5 others
- **Apr** **[Arrakis Therapeutics](https://millionrounds.com/company/arrakis-therapeutics)** Series B · US · FinSMEs **$75M** With 13 others
- **Feb** **[HiberCell](https://millionrounds.com/company/hibercell)** Series A · US · FinSMEs **$61M** With 3 others
- **2018** 5 rounds
- **Jul** **[Presage Biosciences](https://millionrounds.com/company/presage-biosciences)** Series D · US · FinSMEs **$6.0M** With 1 other
- **Jun** **[Sutro](https://millionrounds.com/company/sutro)** Series E · US · FinSMEs **$85M** With 17 others
- **Mar** **[Ideaya](https://millionrounds.com/company/ideaya)** Series B · US · FinSMEs **$94M** With 12 others
- **Feb** **[Celularity](https://millionrounds.com/company/celularity)** US · FinSMEs **$250M** With 7 others
- **Jan** **[Ribon Therapeutics](https://millionrounds.com/company/ribon-therapeutics)** Series B · US · Marketwatch **$65M** With 7 others
- **2017** 5 rounds
- **Dec** **[FLX Bio](https://millionrounds.com/company/flx-bio)** Series C · US · Vcnewsdaily **$60M** With 4 others
- **Aug** **[Armo Biosciences](https://millionrounds.com/company/armo-biosciences)** Series C · US · FinSMEs **$67M** With 10 others
- **Jul** **[Evelo Biosciences](https://millionrounds.com/company/evelo-biosciences)** Series B · US · FinSMEs **$50M** With 4 others
- **Mar** **[Grail](https://millionrounds.com/company/grail)** Series B · US · FinSMEs **$900M** With 7 others
- **Feb** **[Arrakis Therapeutics](https://millionrounds.com/company/arrakis-therapeutics)** Series A · US · FinSMEs **$38M** With 4 others
- **2016** 2 rounds
- **Dec** **[Cota](https://millionrounds.com/company/cota)** US · FinSMEs **$18M** With 2 others
- **Aug** **[Cleave Bioscience](https://millionrounds.com/company/cleave-bioscience)** Series B · US · FinSMEs **$37M** With 2 others
- **2015** 1 round
- **Apr** **[CRISPR THERAPEUTICS](https://millionrounds.com/company/crispr-therapeutics)** Series B · GB **$64M** With 5 others
- **2014** 6 rounds
- **Dec** **[Flexus Biosciences](https://millionrounds.com/company/flexus-biosciences)** Series B · US **$38M** With 2 others
- **Oct** **[Sequenta](https://millionrounds.com/company/sequenta)** Venture · US **Undisclosed** Sole investor
- **Sept** **[VentiRx Pharmaceuticals](https://millionrounds.com/company/ventirx-pharmaceuticals)** Series B · US **$51M** With 4 others
- **Jun** **[NantHealth](https://millionrounds.com/company/nanthealth)** Growth · US **$25M** Sole investor
- **Feb** **[Epizyme](https://millionrounds.com/company/epizyme)** US **$10M** Sole investor
- **Jan** **[Atara Biotherapeutics](https://millionrounds.com/company/atara-biotherapeutics)** Series B · US **$14M** With 6 others
- **2013** 4 rounds
- **Dec** **[Atara Biotherapeutics](https://millionrounds.com/company/atara-biotherapeutics)** Series B · US **$39M** With 5 others
- **Dec** **[Sutro Biopharma](https://millionrounds.com/company/sutro-biopharma)** Series D · US · finsmes.com **$26M** With 5 others
- **Jul** **[Acetylon Pharmaceuticals](https://millionrounds.com/company/acetylon-pharmaceuticals)** Growth · US · bostinno.streetwise.co **$100M** Sole investor
- **Jul** **[Tengion](https://millionrounds.com/company/tengion)** Series D · US · wraltechwire.com **$34M** Sole investor
- **2012** 3 rounds
- **Nov** **[Mirna Therapeutics](https://millionrounds.com/company/mirna-therapeutics)** Series D · US · sec.gov **$17M** With 10 others
- **Oct** **[VentiRx Pharmaceuticals](https://millionrounds.com/company/ventirx-pharmaceuticals)** Venture · US · pevc.dowjones.com **$35M** Sole investor
- **Feb** **[Acetylon Pharmaceuticals](https://millionrounds.com/company/acetylon-pharmaceuticals)** Growth · US · finance.yahoo.com **$15M** Sole investor
- **2011** 2 rounds
- **Dec** **[Acceleron Pharma](https://millionrounds.com/company/acceleron-pharma)** Series F · US · finsmes.com **$30M** Sole investor
- **Nov** **[Agios Pharmaceuticals](https://millionrounds.com/company/agios-pharmaceuticals)** Series C · US · finsmes.com **$78M** With 3 others
- **2010** 1 round
- **Jun** **[FerroKin Biosciences](https://millionrounds.com/company/ferrokin-biosciences)** Series B · US · fiercebiotech.com **$12M** With 4 others
- **2007** 1 round
- **Jan** **[Cylene Pharmaceuticals](https://millionrounds.com/company/cylene-pharmaceuticals)** Series C · US · rctech.com **$44M** With 7 others

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

## The team

We hold **1** person at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.

## What the register says

From the firm's own filings with the SEC, which it must file accurately by law

**3+** funds on file numbered funds in its name

## Exits from the portfolio

Companies it backed that were later bought or listed **3 in all**

**[Flexus Biosciences](https://millionrounds.com/company/flexus-biosciences)** Bought by [Bristol-Myers Squibb](https://millionrounds.com/fund/bristol-myers-squibb) **$1.3B** Feb 2015

**[Sequenta](https://millionrounds.com/company/sequenta)** Bought by Adaptive Biotechnologies **Undisclosed** Jan 2015

**[Agios Pharmaceuticals](https://millionrounds.com/company/agios-pharmaceuticals)** Listed **$86M** Jun 2013

An exit counts when it came after the firm's first round in the company. From historical deal records.

## Companies it bought

Acquisitions by the firm itself

**[Receptos](https://millionrounds.com/company/receptos)** **$7.3B** Jul 2015

**Quanticel Pharmaceuticals** **$485M** Apr 2015

**[Avila Therapeutics](https://millionrounds.com/company/avila-therapeutics)** **$350M** Jan 2012

**Abraxis BioScience** **$2.9B** Jun 2010

**[Gloucester Pharmaceuticals](https://millionrounds.com/company/gloucester-pharmaceuticals)** **$640M** Dec 2009

**[Pharmion](https://millionrounds.com/company/pharmion)** **$2.9B** Nov 2007

## The cheque

Series B Series D Series C

Median round joined **$61M** the round, not its cheque Alone, median **$30M**

Led 0 of 33 rounds **0%**

- **Sole investor:** 8 rounds
- **Last cheque:** Jul 2019
- **Exits:** 3 from the portfolio

Rounds by stage said on their site

- Series B *12*
- Series D *5*
- Series C *4*
- Growth *3*
- Series A *2*

Cheques by year Led Joined

2007 2019

Often in the room with

- [Alexandria Real Estate Equities](https://millionrounds.com/fund/alexandria) 5
- [Google Ventures](https://millionrounds.com/fund/gv) 5
- [Osage University Partners](https://millionrounds.com/fund/osage-university-partners) 4
- [Amgen Ventures](https://millionrounds.com/fund/amgen-ventures) 3
- [DAG Ventures](https://millionrounds.com/fund/dag-ventures) 3
- [Domain Associates](https://millionrounds.com/fund/domain-associates) 3

**Pitching Celgene?** Put them on your fundraising board with this record on the card, and follow them to hear when they write a new cheque.

Add to your CRM *→*

## Who they invest alongside

The investors most often in the same rounds as Celgene. A count of rooms they were both in, not a relationship either has claimed.

[**Alexandria Real Estate Equities** VC firm **5** rounds together](https://millionrounds.com/fund/alexandria)[**Google Ventures** Corporate VC **5** rounds together](https://millionrounds.com/fund/gv)[**Osage University Partners** VC firm **4** rounds together](https://millionrounds.com/fund/osage-university-partners)[**Amgen Ventures** Growth equity **3** rounds together](https://millionrounds.com/fund/amgen-ventures)[**DAG Ventures** VC firm **3** rounds together](https://millionrounds.com/fund/dag-ventures)[**Domain Associates** VC firm **3** rounds together](https://millionrounds.com/fund/domain-associates)[**Kleiner Perkins Caufield & Byers** VC firm **3** rounds together](https://millionrounds.com/fund/kleiner-perkins-caufield-and-byers)[**Pfizer** Corporate VC **3** rounds together](https://millionrounds.com/fund/pfizer)[**The Column Group** VC firm **3** rounds together](https://millionrounds.com/fund/the-column-group)[**6 Dimensions Capital** VC firm **2** rounds together](https://millionrounds.com/fund/6-dimensions-capital)[**ARCH Venture Partners** VC firm **2** rounds together](https://millionrounds.com/fund/arch-venture-partners)[**Abingworth** VC firm **2** rounds together](https://millionrounds.com/fund/abingworth)

## Recently backed

The latest companies Celgene put money into.

[**Arrakis Therapeutics** $75M · Apr 2019](https://millionrounds.com/company/arrakis-therapeutics)[**HiberCell** $61M · Feb 2019](https://millionrounds.com/company/hibercell)[**Presage Biosciences** $6.0M · Jul 2018](https://millionrounds.com/company/presage-biosciences)[**Celularity** $250M · Feb 2018](https://millionrounds.com/company/celularity)[**Ribon Therapeutics** $65M · Jan 2018](https://millionrounds.com/company/ribon-therapeutics)[**Evelo Biosciences** $50M · Jul 2017](https://millionrounds.com/company/evelo-biosciences)

## Quick answers about Celgene

### What does Celgene invest in?

Celgene invests most often at Series B and Series D (65% of the rounds on record).

### How active is Celgene?

33 investments on record, 0 of them in the last 12 months. The most recent was in Jul 2019.

### What has Celgene invested in recently?

Its most recent investments on record: GNS Healthcare (Series D, Jul 2019), Arrakis Therapeutics (Series B, Apr 2019) and HiberCell (Series A, Feb 2019).

### How big are Celgene's cheques?

The median round it joins is $61M.

### Does Celgene lead rounds?

Rarely, if at all: none of its 33 investments on record names it as the lead.

### Where does Celgene invest?

Most of the companies it backs are in the United States (97%).

### Is Celgene investing now?

No investments in the last 12 months; the latest was in Jul 2019.

### Who does Celgene invest alongside?

Most often Alexandria Real Estate Equities (5 rounds together), Google Ventures (5 rounds together) and Osage University Partners (4 rounds together).

## Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Find similar investorsOpen your CRM

Built from the rounds we watched, its filings and its own website, refreshed every night. [How we count](https://millionrounds.com/methodology) · [Report a correction](https://millionrounds.com/corrections?slug=celgene) · [Is this your firm? Claim it](https://millionrounds.com/claim?org=celgene)